drugset / Trial / NCT01969643
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Timeline
- Start
- 2013-10-22
- Primary completion
- 2023-02-04
- Completion
- 2023-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | ladiratuzumab vedotin | Unknown | — | Intravenous |